Name | Value |
---|---|
Revenues | 116.2M |
Cost of Revenue | 26.5M |
Gross Profit | 89.7M |
Operating Expense | 90.2M |
Operating I/L | -6.3M |
Other Income/Expense | 4.7M |
Interest Income | 4.7M |
Pretax | -1.6M |
Income Tax Expense | -1.5M |
Net Income/Loss | -0.0M |
Axonics, Inc. is a medical technology company specializing in sacral neuromodulation (SNM) systems for treating overactive bladder, urinary urge incontinence, urinary urgency frequency, fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the sacral nerve, reducing symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent for female stress urinary incontinence. Axonics sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally.